Hyponatremia in Clinical Practice: A Comprehensive Review

Dr Neeraj Manikath , claude.ai

Abstract

Hyponatremia, defined as serum sodium concentration <135 mmol/L, represents the most common electrolyte disorder in clinical practice, affecting up to 30% of hospitalized patients. Despite its frequency, hyponatremia remains underrecognized and suboptimally managed, contributing to significant morbidity and mortality. This review provides a structured, evidence-based approach to the diagnosis and management of hyponatremia, emphasizing practical clinical algorithms, common pitfalls, and contemporary management strategies. We highlight diagnostic pearls that enhance clinical reasoning and discuss recent advances in treatment, including the role of vaptans and strategies to prevent osmotic demyelination syndrome.

Keywords: Hyponatremia, SIADH, osmotic demyelination syndrome, hypotonic hyponatremia, vaptans

Introduction

Hyponatremia affects approximately 15-30% of hospitalized patients and up to 7% of healthy ambulatory populations.¹ The condition carries substantial clinical significance: even mild hyponatremia (130-135 mmol/L) increases fall risk, fracture rates, and mortality in elderly patients.² Severe acute hyponatremia can cause cerebral edema, seizures, coma, and death, while overly rapid correction risks osmotic demyelination syndrome (ODS), formerly known as central pontine myelinolysis.³

The complexity of hyponatremia lies not in its detection but in its systematic evaluation and safe correction. This review provides a practical framework for diagnosis and management, drawing from current guidelines and recent literature.

Pathophysiology: Understanding Water Balance

Sodium concentration reflects the ratio of total body sodium to total body water rather than absolute sodium content. Hyponatremia fundamentally represents water excess relative to sodium, typically mediated through impaired water excretion by the kidneys.

The Central Role of Antidiuretic Hormone (ADH)

Water homeostasis depends primarily on ADH (arginine vasopressin), released from the posterior pituitary in response to:

Increased plasma osmolality (>280 mOsm/kg)
Decreased effective circulating volume
Non-osmotic stimuli (pain, nausea, medications, stress)

ADH acts on V2 receptors in renal collecting ducts, inserting aquaporin-2 channels that increase water reabsorption. In most hyponatremia cases, ADH activity is inappropriately elevated relative to plasma osmolality.⁴

Pearl #1: The Osmolar Gap

When measured serum osmolality significantly exceeds calculated osmolality (>10 mOsm/kg), consider unmeasured osmoles such as mannitol, glycine (post-TURP), ethanol, methanol, or ethylene glycol. This distinction prevents misdiagnosis of pseudohyponatremia.

Clinical Presentation and Assessment

Symptomatology: The Rate Matters

Clinical manifestations depend primarily on the rate and severity of sodium decline:

Acute Hyponatremia (<48 hours):

Early: Nausea, headache, confusion, lethargy
Progressive: Vomiting, cardiorespiratory distress, seizures
Severe: Obtundation, coma, respiratory arrest, brainstem herniation
Death can occur with sodium <120 mmol/L developing rapidly

Chronic Hyponatremia (>48 hours):

Often oligosymptomatic until sodium <120 mmol/L
Subtle cognitive impairment, gait instability
Increased falls and fractures in elderly patients⁵
Osteoporosis correlation in chronic cases

Pearl #2: The "Too Well" Sign

If a patient with sodium <115 mmol/L appears relatively well without significant neurologic symptoms, the hyponatremia is likely chronic (>48 hours). The brain has adapted through osmolyte extrusion, and rapid correction becomes dangerous. Conversely, severe symptoms with modest hyponatremia (125-130 mmol/L) suggest acute development requiring urgent intervention.

Diagnostic Approach: The Systematic Method

Step 1: Confirm True Hypotonic Hyponatremia

First, exclude pseudohyponatremia and hypertonic hyponatremia:

Pseudohyponatremia:

Severe hyperlipidemia (triglycerides >1500 mg/dL)
Severe hyperproteinemia (multiple myeloma)
Laboratory artifact with older flame photometry methods
Hack: Modern ion-selective electrode methods eliminate most pseudohyponatremia

Hypertonic Hyponatremia:

Hyperglycemia: Sodium decreases ~1.6 mmol/L per 100 mg/dL glucose rise above 100 mg/dL⁶
Corrected Na⁺ = Measured Na⁺ + [(Glucose - 100)/100] × 1.6
Mannitol administration, glycine absorption during TURP

Step 2: Assess Volume Status

Clinical volume assessment guides diagnosis:

Hypovolemic Hyponatremia:

Volume depletion with both sodium and water loss, but proportionally more sodium loss
Renal losses: Diuretics, salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency
Extra-renal losses: Vomiting, diarrhea, third-spacing (pancreatitis, burns), excessive sweating

Euvolemic Hyponatremia:

No clinically apparent volume depletion or overload
SIADH (most common)
Glucocorticoid deficiency
Hypothyroidism
Primary polydipsia
Medications

Hypervolemic Hyponatremia:

Total body sodium increased, but total body water increased even more
Cirrhosis, heart failure, nephrotic syndrome, advanced chronic kidney disease
Characterized by edema and third-spacing

Pearl #3: The Urine Sodium Discriminator

Measure spot urine sodium to differentiate:

Volume Status	Urine Sodium	Causes
Hypovolemic	<30 mmol/L	Extra-renal losses (GI, skin, third-space)
Hypovolemic	>40 mmol/L	Renal losses (diuretics, salt-wasting, adrenal insufficiency)
Euvolemic	>40 mmol/L	SIADH, hypothyroidism, glucocorticoid deficiency
Euvolemic	<30 mmol/L	Primary polydipsia, tea and toast diet
Hypervolemic	<30 mmol/L	Cirrhosis, heart failure (before diuretics)
Hypervolemic	>40 mmol/L	Kidney disease, cirrhosis/CHF on diuretics

Step 3: Measure Urine Osmolality

Urine osmolality reveals kidney water-handling capacity:

Urine Osm <100 mOsm/kg: Maximum dilution achieved, suggests primary polydipsia or beer potomania (overwhelming water intake)
Urine Osm >100 mOsm/kg: Impaired water excretion, suggests inability to dilute urine appropriately (SIADH, hormonal deficiencies, kidney dysfunction)

Oyster #1: The Exercise-Associated Hyponatremia (EAH) Trap

Endurance athletes (marathoners, triathletes) can develop acute symptomatic hyponatremia from excessive hypotonic fluid intake combined with non-osmotic ADH release. Unlike typical SIADH, these patients may appear volume overloaded. Treatment differs from standard hyponatremia: fluid restriction and, if symptomatic, hypertonic saline. Aggressive isotonic fluid resuscitation worsens the condition.⁷

Common Etiologies: Deep Dive

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

SIADH represents the most common cause of euvolemic hyponatremia in hospitalized patients. Diagnostic criteria include:⁸

Hypotonic hyponatremia (serum osmolality <275 mOsm/kg)
Urine osmolality >100 mOsm/kg (typically >300 mOsm/kg)
Urine sodium >40 mmol/L (on normal salt intake)
Clinical euvolemia (no edema, dehydration, or hypotension)
Normal thyroid, adrenal, and kidney function
No recent diuretic use

Common Causes of SIADH:

Malignancies:

Small cell lung cancer (most classic association)
Head and neck cancers, gastrointestinal malignancies
Ectopic ADH production

CNS Disorders:

Meningitis, encephalitis, brain abscess
Subarachnoid hemorrhage, subdural hematoma
Stroke, traumatic brain injury
Guillain-Barré syndrome

Pulmonary Diseases:

Pneumonia (bacterial, viral, atypical)
Tuberculosis, aspergillosis
Positive pressure ventilation
Acute respiratory failure

Medications: (Extensive list)

SSRIs (especially in elderly patients)
Carbamazepine, oxcarbazepine, valproate
Cyclophosphamide, vincristine, cisplatin
Proton pump inhibitors
NSAIDs
Opiates
MDMA (ecstasy)

Postoperative State:

Non-osmotic ADH release from surgical stress, pain, nausea

Pearl #4: The SIADH Variants

Reset osmostat: Sodium regulated at lower set point (125-130 mmol/L), patient otherwise well, water loading test shows appropriate dilution at new baseline. Seen in malnutrition, chronic illness, pregnancy.
Cerebral/renal salt wasting: Mimics SIADH but patient is truly volume depleted. Differentiation: measure serum uric acid (<4 mg/dL suggests SIADH due to increased urinary uric acid excretion; >4 mg/dL suggests true volume depletion).⁹

Thiazide Diuretic-Induced Hyponatremia

Thiazides impair urinary dilution by blocking sodium-chloride cotransporter in distal tubule, preventing free water generation. This condition typically affects elderly women within 2 weeks of thiazide initiation.¹⁰

Mechanism:

Impaired free water excretion
Volume depletion stimulating ADH release
Potassium depletion augmenting ADH effect

Clinical Recognition:

Recent thiazide initiation
Urine sodium often >40 mmol/L despite volume depletion
Hypokalemia frequently coexists
Can be severe (sodium <120 mmol/L)

Management:

Discontinue thiazide permanently
Isotonic saline if symptomatic
Potassium repletion
Most resolve within 48-72 hours

Adrenal Insufficiency

Cortisol deficiency causes hyponatremia through multiple mechanisms:

Increased ADH release
Decreased cardiac output and GFR
Increased proximal tubule sodium reabsorption
Direct effect on water permeability in collecting duct

Key Distinguishing Features:

Hyperkalemia (if mineralocorticoid deficiency present)
Metabolic acidosis
Hypotension
Hypoglycemia
Eosinophilia, lymphocytosis

Hack: Always check 8 AM cortisol in unexplained euvolemic hyponatremia. If <3 μg/dL, diagnostic of adrenal insufficiency; if >15 μg/dL, excludes it; if 3-15 μg/dL, perform ACTH stimulation test.

Hypothyroidism

Severe hypothyroidism causes hyponatremia through:

Decreased cardiac output reducing renal perfusion
Increased ADH secretion
Impaired free water excretion

Clinical hyponatremia typically requires TSH >50-100 mIU/L. Isolated mild hypothyroidism rarely causes significant hyponatremia; consider alternative diagnoses.

Primary Polydipsia

Compulsive water drinking overwhelms renal excretory capacity (maximum ~800-1000 mL/hour in healthy individuals). Seen in:

Psychiatric patients (psychogenic polydipsia)
Potomania syndromes (beer, tea and toast)
Institutionalized patients with altered thirst

Diagnostic Clues:

Very dilute urine (Osm <100 mOsm/kg)
Urine sodium <30 mmol/L
Water intake history >3-4 L/day
Rapid fluctuations in sodium with water restriction

Oyster #2: Beer Potomania

Chronic excessive beer consumption (>4-6 L/day) with poor protein/solute intake creates "solute-limited" water excretion. Beer provides minimal osmoles (calories from ethanol don't generate urinary osmoles). Without adequate daily solute intake (~600-800 mOsm required), even modest water intake cannot be excreted. Treatment includes solute repletion (food, protein) along with water restriction. Rapid correction risk is high—these patients often present with severe chronic hyponatremia and begin eating/excreting water once hospitalized.¹¹

Treatment: The Balancing Act

Management principles must balance two opposing risks:

Undertreating: Allowing persistent severe symptoms or cerebral edema
Overcorrecting: Causing osmotic demyelination syndrome

Acute Symptomatic Hyponatremia (<48 Hours with Severe Symptoms)

Indications for Urgent Treatment:

Severe symptoms: Seizures, obtundation, coma, respiratory distress
Sodium typically <120 mmol/L
Acute onset (<48 hours) with rapid development

Initial Management:

3% Hypertonic Saline: 100-150 mL IV bolus over 10-20 minutes
Repeat: Check sodium after 20 minutes; if symptoms persist and sodium rise <2 mmol/L, give another 100-150 mL bolus
Goal: Increase sodium by 4-6 mmol/L in first 1-4 hours (enough to reverse acute cerebral edema)
Monitoring: Check sodium every 2-4 hours initially

Formulas:

3% saline contains 513 mmol/L sodium
Each 1 mL/kg raises serum sodium ~1 mmol/L
Sodium deficit = 0.6 × body weight (kg) × (target Na⁺ - current Na⁺)

Pearl #5: The Acute Treatment Algorithm

Give 2 mL/kg (100-150 mL) of 3% saline over 10-20 minutes
Recheck sodium in 20 minutes
If <2 mmol/L rise and symptoms persist, repeat dose
Maximum 2-3 boluses in first hour
Goal: 4-6 mmol/L rise in 4-6 hours to abort cerebral edema
Then SLOW DOWN to avoid exceeding 8 mmol/L in 24 hours

Chronic Hyponatremia (>48 Hours or Asymptomatic/Mildly Symptomatic)

Key Principle: Avoid rapid overcorrection to prevent ODS

**Correction Limits:**¹²

First 24 hours: <8-10 mmol/L rise (10 mmol/L maximum in high-risk patients)
First 48 hours: <18 mmol/L rise
Never exceed: 0.5 mmol/L per hour

High-Risk Patients for ODS:

Chronic hyponatremia (>48 hours)
Severe hyponatremia (<120 mmol/L)
Hypokalemia (correct this first—potassium repletion raises sodium)
Malnutrition, alcoholism, liver disease
Hypoxia, advanced liver disease

Treatment by Etiology

SIADH:

Treat underlying cause (pneumonia, discontinue offending medication)
Fluid restriction: 500-800 mL/day (below insensible losses + urine output)
Salt tablets: 1-3 g TID with loop diuretic (creates medullary washout, impairs urine concentration)
Urea: 15-30 g/day in divided doses (osmotic diuresis, well-tolerated long-term)
Vaptans: Tolvaptan, conivaptan (see below)

Hypovolemic Hyponatremia:

Isotonic saline (0.9% NaCl) if true volume depletion
Correct underlying cause (stop diuretics, treat vomiting/diarrhea)
Monitor closely—volume repletion turns off ADH, rapid correction can occur

Hypervolemic Hyponatremia:

Water restriction (1-1.5 L/day)
Treat underlying condition (optimize heart failure, cirrhosis management)
Loop diuretics with salt supplementation if needed
Avoid rapid correction—rarely symptomatic

Hack: The Furst Formula for Safe 3% Saline

To raise sodium by 1 mmol/L: Infuse 3% saline at rate = (Body weight in kg)/2 mL/hour

70 kg patient: 35 mL/hour raises sodium ~1 mmol/L per hour
Easily titrate to desired correction rate
Example: Target 6 mmol/L rise over 6 hours = 35 mL/hour for 6 hours

Vaptans: Vasopressin Receptor Antagonists

Selective V2 receptor antagonists block ADH action, promoting aquaresis (free water excretion without electrolyte loss).

Available Agents:

Tolvaptan: Oral, 15-60 mg daily (FDA-approved for euvolemic/hypervolemic hyponatremia)
Conivaptan: IV, 20 mg load then 20-40 mg/24h infusion (approved for hospitalized patients)

Indications:

Euvolemic hyponatremia (SIADH) resistant to fluid restriction
Hypervolemic hyponatremia (heart failure, cirrhosis) with fluid overload
Moderate-severe chronic hyponatremia requiring hospitalization

Advantages:

Predictable sodium correction
Allows oral intake without worsening hyponatremia
Improves quality of life in chronic SIADH¹³

Limitations:

Risk of overcorrection: Close monitoring required (check sodium every 4-6 hours initially)
Expensive
Hepatotoxicity concern (tolvaptan—requires liver monitoring)
Not for acute symptomatic hyponatremia (too slow onset)
Contraindicated in hypovolemic hyponatremia, anuric kidney failure

Pearl #6: Vaptan Dosing Strategy

Start tolvaptan 15 mg in morning (allows daylight monitoring)
Check sodium at 4, 8, and 24 hours
Goal 4-6 mmol/L rise in 24 hours
If >6 mmol/L rise in 8 hours, give desmopressin 2-4 μg IV/SC to prevent further rise
Can re-lower sodium with D5W infusion if overshot

Osmotic Demyelination Syndrome: The Feared Complication

ODS results from overly rapid correction of chronic hyponatremia, causing osmotic stress in oligodendrocytes leading to demyelination, particularly in pons (central pontine myelinolysis) and extrapontine sites.³

Pathophysiology

During chronic hyponatremia, brain cells adapt by extruding organic osmolytes (glutamate, taurine, myoinositol) to prevent cerebral edema. This adaptation takes 48-72 hours. Rapid sodium correction doesn't allow osmolyte reaccumulation, creating intracellular dehydration and oligodendrocyte apoptosis.

Clinical Presentation

Timeline: Biphasic

Initial improvement: 1-2 days post-correction with symptom resolution
Neurologic deterioration: 2-7 days post-correction with progressive symptoms

Symptoms:

Dysarthria, dysphagia
Behavioral changes, confusion, delirium
Quadriparesis or paraparesis
Locked-in syndrome (in severe central pontine cases)
Seizures, coma
Often irreversible; mortality 25-50% in severe cases

Diagnosis:

MRI (gold standard): Hyperintense T2/FLAIR signal in pons or extrapontine sites
Imaging changes may lag clinical presentation by 2-4 weeks
CT typically normal

Pearl #7: The ODS Risk Stratification

Highest Risk Patients:

Sodium <105 mmol/L
Duration >48 hours (especially if weeks to months)
Hypokalemia (unpredictably rapid rise when corrected)
Malnutrition (alcoholism, eating disorders)
Advanced liver disease
Hypoxic states
Burn patients

Prevention

Absolute Rules:

Limit correction to <8 mmol/L in 24 hours (some say 6 mmol/L for high-risk)
Limit correction to <18 mmol/L in 48 hours
Check sodium every 2-4 hours during active treatment
If limits exceeded, RELOWER sodium immediately

Oyster #3: Rescuing Overcorrection

If sodium rises too rapidly (>6-8 mmol/L in 24 hours):

Immediate actions: Stop all hypertonic saline/sodium-containing fluids
Relower sodium: Give desmopressin (DDAVP) 2-4 μg IV/SC q8-12h AND infuse D5W at 3-6 mL/kg/hour
Goal: Return sodium to level where correction rate is acceptable
Example: If sodium rose from 115 to 127 (12 mmol rise) in 12 hours, relower to ~120 over next 6-12 hours
Evidence: Case series suggest this approach may prevent or mitigate ODS¹⁴

Mechanism: DDAVP stimulates aquaporin-2 insertion, promoting water reabsorption, while D5W provides free water substrate.

Special Populations and Scenarios

Postoperative Hyponatremia

Common due to:

Non-osmotic ADH release (pain, nausea, stress)
Hypotonic IV fluid administration
High risk in menstruating women (50× increased risk of neurologic injury)

Management:

Minimize hypotonic fluid use perioperatively
Isotonic saline or balanced crystalloids preferred
High index of suspicion for acute symptomatic hyponatremia

Hyponatremia in Cirrhosis

Dilutional hyponatremia from:

Portal hypertension → splanchnic vasodilation → perceived hypovolemia
High ADH and renin-aldosterone activation
Associated with poor prognosis (MELD-Na includes sodium)

Treatment Challenges:

Aggressive correction increases ODS risk (malnourished, liver disease)
Fluid restriction difficult with ascites requiring paracentesis
Albumin infusions (after large-volume paracentesis) can raise sodium
Vaptans may help but hepatotoxicity concern with tolvaptan

Hyponatremia in Heart Failure

Marker of disease severity and poor prognosis. Associated with:

High ADH and neurohumoral activation
Impaired renal perfusion
Diuretic use

Management:

Optimize heart failure treatment (ACE inhibitors, beta-blockers, diuretics)
Fluid restriction (1-1.5 L/day)
Tolvaptan approved for hypervolemic hyponatremia in heart failure¹⁵
Avoid aggressive correction—chronic, adapted

Exercise-Associated Hyponatremia (Covered Earlier)

MDMA (Ecstasy)-Induced Hyponatremia

Mechanism:

Direct SIADH effect
Compulsive water drinking at rave events
Increased insensible losses from dancing

Often affects young patients with acute severe symptomatic hyponatremia requiring hypertonic saline.

Diagnostic Pitfalls and Clinical Pearls Summary

Pearl #8: The Hypokalemia Correction Effect

Potassium and sodium compete for intracellular space. Correcting hypokalemia causes potassium to shift intracellularly, displacing sodium into extracellular space, raising serum sodium. In hyponatremic patients with hypokalemia, ALWAYS correct potassium slowly and monitor sodium closely—rapid potassium repletion can cause unpredictably rapid sodium rise and ODS risk.

Pearl #9: The Urine-to-Plasma Electrolyte Ratio

Calculate: (Urine Na⁺ + Urine K⁺) / Plasma Na⁺

If ratio >1: Urine is hypertonic relative to plasma sodium; patient will become more hyponatremic with ongoing urine production
If ratio <1: Urine is hypotonic; patient's sodium will rise with ongoing urine output
Guides fluid therapy: If ratio >1 in SIADH, isotonic saline will worsen hyponatremia—use 3% saline or fluid restriction instead¹⁶

Pearl #10: The "Slow and Steady" Mantra

In chronic asymptomatic hyponatremia, slower is always better. Target 4-6 mmol/L rise per 24 hours. No urgency exists unless patient is actively seizing or obtunded. The brain has adapted; your job is to reverse this adaptation slowly.

Monitoring and Follow-Up

Acute Phase (First 24-48 Hours)

Serum sodium: Every 2-4 hours during active treatment
Serum potassium: Every 4-6 hours (if replacing)
Urine output: Hourly initially
Neurologic checks: Every 1-2 hours
Urine electrolytes: Every 6-12 hours in complex cases

Maintenance Phase

Daily sodium checks until stable >130 mmol/L
Address underlying cause
Transition to chronic management (fluid restriction, medications)
Patient education about fluid intake

Outpatient Management

Weekly sodium checks initially after discharge
Monthly once stable
Educate about symptoms of recurrence
Medication review (avoid thiazides, SSRIs if caused hyponatremia)

Key Take-Home Messages

Rate of development determines symptoms and treatment urgency: Acute symptomatic hyponatremia requires immediate intervention; chronic hyponatremia demands cautious correction.
Systematic approach is essential: Confirm hypotonic hyponatremia → assess volume status → measure urine sodium and osmolality → determine etiology.
SIADH is a diagnosis of exclusion: Rule out thyroid and adrenal insufficiency, medications, and alternative causes.
Correction limits are absolute: Never exceed 8-10 mmol/L rise in 24 hours for chronic hyponatremia to prevent ODS.
Hypertonic saline is for acute symptomatic patients: Small boluses (100-150 mL 3% saline) to raise sodium 4-6 mmol/L acutely, then slow correction.
High-risk patients require extreme caution: Alcoholics, malnourished, liver disease, severe hyponatremia (<105 mmol/L), hypokalemia—aim for lower end of correction range.
Monitor, monitor, monitor: Frequent sodium checks during correction prevent overcorrection disasters.
Potassium matters: Hypokalemia must be corrected slowly to avoid unpredictable rapid sodium rises.
Urine electrolytes guide therapy: Urine sodium, osmolality, and urine-to-plasma electrolyte ratio inform fluid choice.
When in doubt, err on the side of slower correction: Undertreating chronic hyponatremia rarely causes harm; overcorrecting can be catastrophic.

Conclusion

Hyponatremia remains a challenging disorder requiring careful diagnostic evaluation and measured therapeutic intervention. The internist must balance the competing risks of undertreating acute symptomatic hyponatremia against the devastating consequences of overly rapid correction in chronic cases. By applying a systematic diagnostic approach, understanding the physiology underlying different etiologies, and adhering to established correction limits, clinicians can safely manage this common electrolyte disorder. Continuous advances in our understanding of SIADH variants, the role of vaptans, and strategies to prevent osmotic demyelination syndrome continue to refine our approach. Above all, hyponatremia management demands vigilance, frequent monitoring, and a commitment to individualized patient care.

References

Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30-S35.
Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71.e1-71.e8.
Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29(3):282-299.
Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17(4):471-503.
Hoorn EJ, Liamis G, Zietse R, Zillikens MC. Hyponatremia and bone: an emerging relationship. Nat Rev Endocrinol. 2011;8(1):33-39.
Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399-403.
Hew-Butler T, Rosner MH, Fowkes-Godek S, et al. Statement of the Third International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015. Clin J Sport Med. 2015;25(4):303-320.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-2072.
Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting? Kidney Int. 2009;76(9):934-938.
Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993;103(2):601-606.
Hilden T, Svendsen TL. Electrolyte disturbances in beer drinkers. A specific "hypo-osmolality syndrome." Lancet. 1975;2(7928):245-246.
Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens. 2010;19(5):493-498.
Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-2112.
Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3(2):331-336.
Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319-1331.
Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a

predictive guide to water restriction. Am J Med Sci. 2000;319(4):240-244.

Author's Note for Medical Educators:

This review synthesizes current evidence with practical clinical wisdom accumulated over decades of bedside teaching. The "pearls" represent high-yield teaching points that crystallize complex concepts, while the "oysters" highlight uncommon but critical scenarios that distinguish experienced clinicians. The systematic approach presented here serves as a reproducible framework for trainees at all levels. When teaching hyponatremia, emphasize the physiologic reasoning behind each diagnostic and therapeutic step—this transforms a memorization exercise into durable clinical reasoning that serves patients for a lifetime.